Niepolski Leszek, Drzewiecka Hanna, Warchoł Wojciech
Department of Physiology, Poznan University of Medical Sciences, Poznań 60-781, Poland.
Department of Biochemistry and Molecular Biology, Poznan University of Medical Sciences, Poznań 60-781, Poland.
Biomed Rep. 2021 Apr;14(4):37. doi: 10.3892/br.2021.1413. Epub 2021 Feb 26.
The aim of the present study was to examine the association between the levels of circulating vascular endothelial growth factor receptor (VEGFR)2 levels, serum lipid composition and plasma receptor for advanced glycation end-products (RAGE) expression in patients undergoing hemodialysis (HD). A total of 50 patients on HD (27 men and 23 women; median age, 66 years; age range 28-88 years; HD mean time, 29.0, 3.9-157.0 months) were enrolled. Age-matched healthy subjects (n=26) were used as the control group. Plasma VEGFR2 and RAGE levels were determined using ELISA. Dyslipidemia (D) in patients on HD was diagnosed according to the Kidney Disease Outcomes Quality Initiative Clinical Practice Guidelines for Managing Dyslipidemias in Chronic Kidney Disease. Circulating VEGFR2, RAGE and serum lipids were compared between dyslipidemic and non-dyslipidemic patients on HD and controls. In patients on HD, the plasma VEGFR2 levels were lower compared with those in the healthy population. D was associated with high plasma VEGFR2 levels. The triglyceride/HDL-cholesterol ratio was strongly associated with plasma VEGFR2 levels. The plasma VEGFR2 concentration was associated with circulating RAGE levels. Therefore, circulating VEGFR2 levels may be partly associated with lipid abnormalities and plasma RAGE levels in patients receiving HD.
本研究的目的是检测接受血液透析（HD）患者的循环血管内皮生长因子受体（VEGFR）2水平、血清脂质成分和晚期糖基化终产物受体（RAGE）表达之间的关联。共纳入50例接受HD治疗的患者（27例男性和23例女性；年龄中位数为66岁；年龄范围28 - 88岁；HD平均时间为29.0个月，3.9 - 157.0个月）。年龄匹配的健康受试者（n = 26）作为对照组。采用酶联免疫吸附测定法（ELISA）测定血浆VEGFR2和RAGE水平。根据《慢性肾脏病血脂异常管理的肾脏病改善全球预后临床实践指南》诊断HD患者的血脂异常（D）。比较HD患者中血脂异常和非血脂异常患者以及对照组之间的循环VEGFR2、RAGE和血清脂质水平。在HD患者中，血浆VEGFR2水平低于健康人群。D与高血浆VEGFR2水平相关。甘油三酯/高密度脂蛋白胆固醇比值与血浆VEGFR2水平密切相关。血浆VEGFR2浓度与循环RAGE水平相关。因此，接受HD治疗患者的循环VEGFR2水平可能部分与脂质异常和血浆RAGE水平有关。
